Broder CC, Dimitrov DS (1997). CC Broder, DS Dimitrov (1997). "HIV and the 7-transmembrane domain receptors". Pathobiology64 (4): 171–9. doi : 10.1159/000164032 . PMID9031325 . "El VIH y el dominio transmembrana de los receptores-7". Patobiología64 (4): 171-9. doi : 10.1159/000164032 . PMID9031325 .
Choe H, Martin KA, Farzan M, et al. (1998). H Choe, Martin KA, M Farzan, et al. (1998). "Structural interactions between chemokine receptors, gp120 Env and CD4". Semin. "Interacciones estructurales entre los receptores de quimioquinas, gp120 env y CD4". Semin.Immunol.10 (3): 249–57. doi : 10.1006/smim.1998.0127 . PMID9653051 . Immunol.10 (3): 249-57. doi : 10.1006/smim.1998.0127 . PMID9653051 .
Sheppard HW, Celum C, Michael NL, et al. (2002). HW Sheppard, C Celum, NL Michael, et al. (2002). "HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion". J. "El VIH-1 en individuos con el genotipo CCR5-Delta32/Delta32: adquisición de inductores de sincitio virus en seroconversión". J.Acquir.Acquir.Immune Defic.Inmune Defic.Syndr.29 (3): 307–13. PMID11873082 . U..29 (3): 307-13. PMID11873082 .
Freedman BD, Liu QH, Del Corno M, Collman RG (2004). Freedman BD, QH Liu, M Del Corno, RG Collman (2004). "HIV-1 gp120 chemokine receptor-mediated signaling in human macrophages". Immunol. "El VIH-1 gp120 quimioquinas mediada por los receptores de señalización en los macrófagos humanos". Immunol.Res.27 (2-3): 261–76. doi : 10.1385/IR:27:2-3:261 . PMID12857973 . Res.27 (2-3): 261-76. doi : 10.1385/IR :27:2-3: 261 . PMID12857973 .
Esté JA (2004). Esté JA (2004). "Virus entry as a target for anti-HIV intervention". Curr. "Virus de entrada como un objetivo para la intervención contra el VIH". Curr.Med.Med.Chem.10 (17): 1617–32. doi : 10.2174/0929867033457098 . PMID12871111 . Chem.10 (17): 1617-1632. doi : 10.2174/0929867033457098 . PMID12871111 .
Zaitseva M, Peden K, Golding H (2003). M Zaitseva, K Peden, Golding H (2003). "HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors". Biochim. "El VIH correceptores: papel de la estructura, modificaciones postraduccionales, y la internalización en la célula de fusión viral y como blanco de los inhibidores de entrada". Biochim.Biophys.Biophys.Acta1614 (1): 51–61. doi : 10.1016/S0005-2736(03)00162-7 . PMID12873765 . Acta1614 (1): 51-61. doi : 10.1016/S0005-2736 (03) 00162-7 . PMID12873765 .
Lee C, Liu QH, Tomkowicz B, et al. (2004). C Lee, QH Liu, B Tomkowicz, et al. (2004). "Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways". J. "Activación macrofágica través de CCR5 y CXCR4 mediada suscitado las vías de señalización-gp120". J.Leukoc.Leukoc.Biol.74 (5): 676–82. doi : 10.1189/jlb.0503206 . PMID12960231 . Biol.74 (5): 676-82. doi : 10.1189/jlb.0503206 . PMID12960231 .
Yi Y, Lee C, Liu QH, et al. (2004). Y Yi, C Lee, QH Liu, et al. (2004). "Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis". J. "Receptor de quimioquinas y la utilización de señalización por los macrófagos de inmunodeficiencia humana virus de tipo 1 gp120: Implicaciones para neuropatogénesis". J.Neurovirol.10 Suppl 1 : 91–6. PMID14982745 . Neurovirol.10 Suppl 1: 91-6. PMID14982745 .
Seibert C, Sakmar TP (2004). C Seibert, TP Sakmar (2004). "Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs". Curr. "Moléculas pequeñas antagonistas de CCR5 y CXCR4: una nueva clase prometedora de la lucha contra el VIH-1 las drogas". Curr.Pharm.Pharm.Des.10 (17): 2041–62. doi : 10.2174/1381612043384312 . PMID15279544 . Des.10 (17): 2041-62. doi : 10.2174/1381612043384312 . PMID15279544 .
Cutler CW, Jotwani R (2006). "Oral mucosal expression of HIV-1 receptors, co-receptors, and alpha-defensins: tableau of resistance or susceptibility to HIV infection?". Adv. Dent. Res.19 (1): 49–51.doi:10.1177/154407370601900110.PMID16672549.
Ajuebor MN, Carey JA, Swain MG (2006). "CCR5 in T cell-mediated liver diseases: what's going on?". J. Immunol.177 (4): 2039–45. PMID16887960 .
Lipp M, Müller G (2006). "Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking". Verhandlungen der Deutschen Gesellschaft für Pathologie87 : 90–101.PMID16888899.
Balistreri CR, Caruso C, Grimaldi MP, et al. (2007). "CCR5 receptor: biologic and genetic implications in age-related diseases". Ann.NYAcad. Sci.1100 : 162–72. doi : 10.1196/annals.1395.014 . PMID17460174 .
Uetsuki T, Naito A, Nagata S, Kaziro Y (1989). "Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha". J. Biol. Chem.264 (10): 5791–8.PMID2564392.
Whiteheart SW, Shenbagamurthi P, Chen L, et al. (1989). "Murine elongation factor 1 alpha (EF-1 alpha) is posttranslationally modified by novel amide-linked ethanolamine-phosphoglycerol moieties. Addition of ethanolamine-phosphoglycerol to specific glutamic acid residues on EF-1 alpha". J. Biol. Chem.264 (24): 14334–41.PMID2569467.
Ann DK, Wu MM, Huang T, et al. (1988). "Retinol-regulated gene expression in human tracheobronchial epithelial cells. Enhanced expression of elongation factor EF-1 alpha". J. Biol. Chem.263 (8): 3546–9.PMID3346208.
Brands JH, Maassen JA, van Hemert FJ, et al. (1986). "The primary structure of the alpha subunit of human elongation factor 1. Structural aspects of guanine-nucleotide-binding sites". Eur. J. Biochem.155 (1): 167–71.doi:10.1111/j.1432-1033.1986.tb09472.x.PMID3512269.
/https%3A%2F%2Fassets.over-blog.com%2Ft%2Fcedistic%2Fcamera.png)
/https%3A%2F%2Fi.ytimg.com%2Fvi%2FDatxERDDm0s%2Fhqdefault.jpg)
/https%3A%2F%2Fi.ytimg.com%2Fvi%2FEPQjXTNmXTg%2Fhqdefault.jpg)
/http%3A%2F%2Fi.ytimg.com%2Fvi%2FOQfkSAicu_o%2Fhqdefault.jpg)